Navigation Links
Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
Date:8/5/2009

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Per Falk, M.D., Ph.D., as vice president for Clinical, Medical and Regulatory Affairs for North America. Dr. Falk joins the U.S. Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk Inc., the Novo Nordisk U.S. affiliate, and senior vice president for Novo Nordisk A/S, North America.

Dr. Falk brings 23 years of medical, research and pharmaceutical experience to his new position where he will lead clinical research and medical affairs in endocrinology and biopharmaceuticals, as well as regulatory affairs and medical communications.

Dr. Falk joined Novo Nordisk in 2002 as a vice president to establish the Experimental Medicine unit in Denmark. Later he served the company in Tokyo where he was responsible for drug development and market authorization of Novo Nordisk's medical entities in Japan and Australia. In 2008, Dr. Falk transitioned to the United States as the associate vice president of Clinical Development & Medical Affairs - Diabetes & Metabolism where he was responsible for clinical development and medical affairs for all of Novo Nordisk's diabetes and metabolism products, including those in development and on the market.

"As a company, Novo Nordisk has exciting opportunities and ambitious targets in diabetes and biopharmaceuticals with the end goal of improving patients' lives," said Jerzy Gruhn, president of Novo Nordisk Inc. "Dr. Falk is a proven asset to the company and is the ideal leader to help drive the development and marketing of new and lifesaving products to benefit millions of patients across the continent."

Prior to joining Novo Nordisk, Dr. Falk held positions as Director for Gastrointestinal Pharmacology and Molecular Biology in AstraZeneca's CV/GI research unit in Molndal, Sweden. He also has served as a lecturer and associate professor at Karolinska Institute, as well as a post-doctoral fellow and instructor in molecular biology and pharmacology at the Washington University School of Medicine in St. Louis.

Dr. Falk earned his M.D. and Ph.D. from the University of Gothenberg in Sweden. He trained in laboratory medicine at Sahlgren University Hospital and internal medicine/gastroenterology at Karolinska University Hospital.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,550 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Launches Twitter Page with Race Car Driver Charlie Kimball
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Novo Nordisk Warns Customers About Stolen Insulin
4. Diabetes Experts Partner With Novo Nordisk to Provide New Patient Materials
5. Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S.
6. Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
7. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
8. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
9. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
10. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
11. Novo Nordisk Files Annual Report with the SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: